Work

In Reply

Year: 2022

Type: letter

Abstract: This letter to the editor responds to remarks on a recently published article about dermatologic events associated with enfortumab vedotin and agrees that education on the prevention and management of such events should be a priority.

Source: The Oncologist

DOI: 10.1093/oncolo/oyac171

Authors: Mario E Lacouture, Anisha B Patel, Jonathan E Rosenberg, Peter H O’Donnell

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, The University of Texas MD Anderson Cancer Center, University of Chicago

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,494

Funders: Astellas Pharma US, Seagen, Astellas Pharma

OpenAlex ID: W4293452607

Cites: 5

Cited by:

Related to: 10